Axon Enterprise, Inc $AXON Shares Purchased by WESPAC Advisors SoCal LLC

WESPAC Advisors SoCal LLC raised its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 37.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,144 shares of the biotechnology company’s stock after purchasing an additional 1,393 shares during the period. WESPAC Advisors SoCal LLC’s holdings in Axon Enterprise were worth $2,185,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Rockefeller Capital Management L.P. lifted its position in shares of Axon Enterprise by 53.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company’s stock worth $6,542,000 after buying an additional 4,002 shares during the last quarter. World Investment Advisors grew its position in shares of Axon Enterprise by 37.1% during the 4th quarter. World Investment Advisors now owns 1,035 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 280 shares during the last quarter. Pure Financial Advisors LLC raised its stake in Axon Enterprise by 6.7% during the fourth quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 23 shares during the period. Tobam raised its stake in Axon Enterprise by 17.3% during the fourth quarter. Tobam now owns 5,833 shares of the biotechnology company’s stock worth $3,313,000 after acquiring an additional 859 shares during the period. Finally, Clearwave Capital LLC bought a new position in Axon Enterprise in the fourth quarter worth about $325,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AXON has been the subject of several recent research reports. TD Cowen lowered their target price on Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Citizens Jmp cut their price target on Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating on the stock in a report on Thursday, May 7th. Wall Street Zen upgraded Axon Enterprise from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Robert W. Baird set a $800.00 target price on Axon Enterprise in a research note on Wednesday, February 25th. Finally, The Goldman Sachs Group set a $535.00 price target on shares of Axon Enterprise in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $712.75.

Insider Buying and Selling

In related news, CRO Cameron Brooks sold 1,242 shares of Axon Enterprise stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $621,000.00. Following the sale, the executive directly owned 49,710 shares in the company, valued at $24,855,000. The trade was a 2.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $485.00, for a total transaction of $753,690.00. Following the completion of the sale, the insider directly owned 34,024 shares of the company’s stock, valued at $16,501,640. The trade was a 4.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 38,989 shares of company stock valued at $19,090,083. Company insiders own 4.20% of the company’s stock.

Axon Enterprise Stock Performance

AXON opened at $423.40 on Friday. The business’s 50 day moving average is $413.25 and its 200-day moving average is $485.61. The stock has a market cap of $34.13 billion, a PE ratio of 170.04, a price-to-earnings-growth ratio of 7.70 and a beta of 1.45. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.90 million. During the same period in the prior year, the company posted $1.47 EPS. The business’s revenue for the quarter was up 33.7% compared to the same quarter last year. On average, analysts predict that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.